Cargando…

Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer

Novel oncology drugs often fail to progress from preclinical experiments to FDA approval. Therefore, determining which preclinical or clinical factors associate with drug activity could accelerate development of effective therapies. We investigated whether preclinical metrics and patient characteris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rybinski, Brad, Hosgood, H. Dean, Wiener, Sara L., Weiser, Daniel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674799/ https://www.ncbi.nlm.nih.gov/pubmed/33251146 http://dx.doi.org/10.3389/fonc.2020.587377

Ejemplares similares

A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs
por: Pan, Elizabeth, et al.
Publicado: (2020)

Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress
por: Wang, Yaning, et al.
Publicado: (2021)

The use of nanoparticles for targeted drug delivery in non-small cell lung cancer
por: Holder, Jessica E., et al.
Publicado: (2023)

A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer
por: Subramaniam, Deepa S., et al.
Publicado: (2018)

Study protocol: a multicentre, prospective, phase II trial of isotoxic hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer
por: Liu, Yue-E, et al.
Publicado: (2020)

Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives
por: Raucher, Drazen, et al.
Publicado: (2018)

Editorial: Preclinical models and emerging technologies to study the effects of the tumor microenvironment on cancer heterogeneity and drug resistance
por: Adriani, Giulia, et al.
Publicado: (2023)

Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
por: Sosa Iglesias, Venus, et al.
Publicado: (2018)

Study protocol of an open-label prospective phase II umbrella study of precise neoadjuvant therapy for patients with stage II-IIIB resectable non-small cell lung cancer (PURPOSE)
por: Wang, Yiyang, et al.
Publicado: (2022)

Lung cancer organoids: models for preclinical research and precision medicine
por: Liu, Yajing, et al.
Publicado: (2023)

Editorial: Targeting metabolism of cancer cells and host to overcome drug resistance: Preclinical and clinical studies
por: Wang, Lishun, et al.
Publicado: (2023)

A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non–small-cell lung cancer
por: Hasegawa, Takaaki, et al.
Publicado: (2016)

Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study
por: Hatton, Matthew Q F, et al.
Publicado: (2019)

Multicentre randomised phase II study of the perioperative administration of flurbiprofen axetil in patients with non-small cell lung cancer: study protocol of the FLAX Study
por: Sakamaki, Kentaro, et al.
Publicado: (2020)

Combined proton radiography and irradiation for high-precision preclinical studies in small animals
por: Schneider, Moritz, et al.
Publicado: (2022)

Ex Vivo Metrics™, a preclinical tool in new drug development
por: Curtis, C Gerald, et al.
Publicado: (2008)

Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation
por: Geier, Brian, et al.
Publicado: (2015)

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
por: Lin, Chen, et al.
Publicado: (2020)

Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer
por: Ozawa, Yuichi, et al.
Publicado: (2020)

Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2013)

The Relation of Obesity-Related Hormonal and Cytokine Levels With Multiple Myeloma and Non-Hodgkin Lymphoma
por: Hosgood, H. Dean, et al.
Publicado: (2018)

Whole-lesion histogram analysis of multiple diffusion metrics for differentiating lung cancer from inflammatory lesions
por: Li, Jiaxin, et al.
Publicado: (2023)

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer
por: Spaans, Johanna N., et al.
Publicado: (2014)

Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer
por: Bates, Amber M., et al.
Publicado: (2021)

Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance
por: Kong, Fanming, et al.
Publicado: (2021)

Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models
por: Zheng, Qingfan, et al.
Publicado: (2022)

Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy
por: Elbanna, May, et al.
Publicado: (2021)

Prognostic Implications of Molecular Subtypes in Primary Small Cell Lung Cancer and Their Correlation With Cancer Immunity
por: Qi, Jing, et al.
Publicado: (2022)

Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models
por: Canals Hernaez, Diana, et al.
Publicado: (2022)

The emerging role of circular RNAs in drug resistance of non-small cell lung cancer
por: Yan, Tinghao, et al.
Publicado: (2022)

Evaluation of the potential of ultrasound-mediated drug delivery for the treatment of ovarian cancer through preclinical studies
por: Wang, Yi-Chao, et al.
Publicado: (2022)

Anti-Angiogenic Drugs Inhibit Interstitial Lung Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer
por: Wang, Yanning, et al.
Publicado: (2022)

Targeted Therapies and Biomarkers in Small Cell Lung Cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2020)

Targeting KRAS in Non-Small Cell Lung Cancer
por: Corral de la Fuente, Elena, et al.
Publicado: (2022)

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)
por: Reckamp, Karen L., et al.
Publicado: (2019)

Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer
por: Wang, Yizhe, et al.
Publicado: (2021)

Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway
por: Jain, Anisha S., et al.
Publicado: (2021)

Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
por: Tibdewal, Anil, et al.
Publicado: (2021)

A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer
por: Khurshid, Humera, et al.
Publicado: (2012)

Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2qbpjdmnu9c57rkbpndb0ruvi3